Corcept Therapeutics Incorporated P/E Ratio 2000–2025
Corcept Therapeutics Incorporated reported 42.44 of price-to-earnings ratio for fiscal 2025. That was 3.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +37.9%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 42.44 | +3.6% |
| FY 2024 | 40.97 | +18.6% |
| FY 2023 | 34.55 | +48.0% |
| FY 2022 | 23.34 | +4.9% |
| FY 2021 | 22.25 | -27.7% |
| FY 2020 | 30.78 | +95.9% |
| FY 2019 | 15.71 | -29.4% |
| FY 2018 | 22.27 | +28.2% |
| FY 2017 | 17.37 | -83.3% |
| FY 2016 | 103.71 | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
| FY 2008 | — | — |
| FY 2007 | — | — |
| FY 2006 | — | — |
| FY 2005 | — | — |
| FY 2004 | — | — |
| FY 2003 | — | — |
| FY 2002 | — | — |
| FY 2001 | — | — |
| FY 2000 | — | — |
Source: Corcept Therapeutics Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open CORT 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Corcept Therapeutics Incorporated reported 42.44 of price-to-earnings ratio for fiscal 2025. That was 3.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +37.9%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Corcept Therapeutics Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCorcept Therapeutics Incorporated — frequently asked questions
What is Corcept Therapeutics Incorporated's price-to-earnings ratio?
Corcept Therapeutics Incorporated (CORT) reported price-to-earnings ratio of 42.44 for fiscal year 2025, per its SEC filings.
How has Corcept Therapeutics Incorporated's price-to-earnings ratio changed over time?
Between fiscal 2000 and 2025, CORT's price-to-earnings ratio declined at roughly 3.5% per year (compound annual rate), from 103.71 to 42.44.
Where does this data come from?
Figures are computed from Corcept Therapeutics Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More CORT financial history
Full CORT fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →